Navigation Links
Abbott’s Laboratories R&D Capabilities Questione

Abbott Laboratories shares fell by 1.3% to close at $43.80 following U.S. Food and Drug Administration (FDA) rejection of its new drug Xinlay. Increased number of scientists and analysts question the efficiency of Abbott’s R&D // , after the rejection of its drug.

The drug that is to be used for the treatment of Prostate cancer failed in its Phase III trial leading to disapproval of the drug by the FDA Panel. Though Abbott is confident of its R&D capabilities and is sure of its other products like Humira, which is used in the treatment of Rheumatoid arthritis and its new drug eluting stent to be approved by the FDA, critics point out that Abbott is not winning in its R&D division as it is doing in Marketing. As FDA as put stringent and tough rules against approval of new drugs following the awful effects of the painkiller drug, Vioxx produced by Merck.

Mike Barr of Victory Capital Management said that, "What's a little disturbing is that Abbott's R&D productivity hasn't been all that great the last few years and looking at the history, they do a very good job at marketing, and it doesn't seem like R&D is up to the same caliber as their marketing." Victory Capital Management owns the shares of Abbott. Another Shareholder of Abbott is The Fifth Third Asset Management, this company is also not happy with Abbott and Mr. Jon Fisher of the company reported that, “It's evident as far as the absolute growth and profitability out of that business and I don't judge by the number of failures, but by the number of successes and how successful they are compared to their pharma peers. They're definitely on the lower end.

Glenn Novarro analyst in Banc of America Securities is optimistic about R&D of Abbott and said that though Xinlay may be a failure its other products in the pipeline like drugs Humira, Simdax, Febuxostat, drug eluting stent and Glucose monitor may succeed. "What is disappointing is that Abbott took a very aggressive approach with t his drug," by filing without a successful Phase III trial, Novarro said. "They clearly made a poor decision." He added, however, that in Abbott's defense, the company isn't a cancer specialist. "They're trying to break into the field, so it's not surprising there would be a stumble along the way."


'"/>




Related medicine news :

1. Dr Reddy’s Laboratories to challenge patents on drug
2. Dr Reddy’s Laboratories launches Hyalosy
3. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
4. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
5. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
6. ICMR to Set up Laboratories to Combat Bird Flu
7. Ranbaxy Laboratories to Be Aided in Drug Research
8. Bangladesh to Set Up HIV/AIDS Diagnosis Laboratories
9. Drug Addicts To Prove ‘Child-Caring Capabilities’ By Clearing Drug Tess
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... , ... January 21, 2017 , ... "ProDOF is the perfect set of tools for ... another subject in a scene," said Christina Austin - CEO of Pixel Film Studios. ... Easily create the illusion of a DSLR racking focus from one area into the ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern ... has recently joined their multi-specialty medical group. The dermatology practice provides general ... , “We’re excited to add this excellent dermatology practice to our group’s medical ...
(Date:1/20/2017)... ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. ... lift is mounted on wheels, it can be wheeled out of the way and stored ... to the deck. "We have transformed the feedback from customers into specific enhancements and created ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... supplement development, announced it attended the January ECRM trade show to continue the marketing ... technologically advanced vitamin C supplement, known for providing 400 percent better absorption than traditional ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon ... acquired Megadyne Medical Products, Inc., a privately ... and markets electrosurgical tools used in operating ... intelligence of Ethicon,s* advanced energy devices with ... a major step forward in Ethicon,s goal ...
(Date:1/20/2017)... Fla. , Jan. 20, 2017 Wells Specialty ... at 3796 Howell Branch Rd in Winter Park, ... Winter Park . Operations have been consolidated into ... Pharmacy is also pleased to announce that Chad Tomlinson ... President of the Company effective immediately. Mr. Tomlinson is a ...
(Date:1/19/2017)... Jan. 19, 2017 The global immunomodulators ... by 2025, according to a new study by ... to be predominantly driven by high R&D investments ... large-scale production of new and therapeutically advanced drugs. ... drugs at an unprecedented rate into the immunomodulators ...
Breaking Medicine Technology: